3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 1/2
1
Status
Completed
3
Terminated
2
Active not recruiting
2
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Conditions
Prostatic Neoplasms
7
Recurrence
2
Neoplasms
2
Prostate Cancer, Hereditary, 7
1
Metastatic Castration-resistant Prostate Cancer
1
Carcinoma
1
Adenocarcinoma
1
Interventions
Dexamethasone
18
Cyclophosphamide
16
fludarabine
11
pomalidomide
9
pembrolizumab
9
carfilzomib
9
daratumumab
7
Rituximab
7
Lenalidomide
7
Calcium Dobesilate
7
fludarabine phosphate
6
Cisplatin
6
Bortezomib
6
Gemcitabine
5
venetoclax
4
elotuzumab
4
isatuximab
3
Vincristine
3
Radiotherapy
3
Prednisone
3
Letrozole
3
Etoposide
3
Doxorubicin
3
Cytarabine
3
tisagenlecleucel
2
selinexor
2
ruxolitinib
2
palbociclib
2
ixazomib
2
dexamethasone 21-phosphate
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Active not recruiting
×
Recurrence
×
cabazitaxel
×
Clear all
NCT01952223
2025-07-30
PEACE2
UNICANCER
Phase 3
Active not recruiting
761 enrolled
NCT02202772
2025-02-24
CGC
Columbia University
Phase 1/2
Active not recruiting
51 enrolled